Aberdeen Group plc Cuts Position in Tarsus Pharmaceuticals, Inc. $TARS

Aberdeen Group plc lowered its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 16.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 51,678 shares of the company’s stock after selling 9,919 shares during the quarter. Aberdeen Group plc’s holdings in Tarsus Pharmaceuticals were worth $3,071,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Osaic Holdings Inc. increased its holdings in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after acquiring an additional 2,782 shares in the last quarter. West Wealth Group LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $202,000. Valeo Financial Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at $209,000. Finally, Allianz Asset Management GmbH acquired a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $227,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS opened at $66.61 on Friday. The business has a 50-day moving average price of $72.54 and a two-hundred day moving average price of $67.64. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $2.83 billion, a P/E ratio of -32.98, a P/E/G ratio of 0.95 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 8.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TARS. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price on the stock. Mizuho began coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $82.29.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.